Low-Dose Nivolumab With or Without Ipilimumab as Adjuvant Therapy After Resection of Melanoma Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancers
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial
Cancers (Basel) 2022 Jan 28;14(3)682, JK Schwarze, S Garaud, YJL Jansen, G Awada, V Vandersleyen, J Tijtgat, A de Wind, P Kristanto, T Seremet, K Willard-Gallo, B NeynsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.